Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.

Autor: Stamp LK; University of Otago, Christchurch, New Zealand. Lisa.Stamp@cdhb.health.nz., Farquhar H; University of Otago, Christchurch, New Zealand., Pisaniello HL; Discipline of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia., Vargas-Santos AB; Department of Internal Medicine, Rio de Janeiro State University, Rio de Janeiro, Brazil., Fisher M; Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.; Prima CARE, Fall River, MA, USA., Mount DB; Renal Divisions, Brigham and Women's Hospital, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA., Choi HK; Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Terkeltaub R; VA San Diego Healthcare System, San Diego, CA, USA.; Department of Medicine, University of California San Diego, La Jolla, CA, USA., Hill CL; Discipline of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, South Australia, Australia., Gaffo AL; University of Alabama at Birmingham, Birmingham, AL, USA.; Birmingham VA Medical Center, Birmingham, AL, USA.
Jazyk: angličtina
Zdroj: Nature reviews. Rheumatology [Nat Rev Rheumatol] 2021 Oct; Vol. 17 (10), pp. 633-641. Date of Electronic Publication: 2021 Jul 30.
DOI: 10.1038/s41584-021-00657-4
Abstrakt: Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the context of advanced CKD varies greatly, and professional bodies have issued conflicting recommendations regarding the treatment of gout in people with concomitant CKD. As a result, confusion exists among medical professionals about the appropriate management of people with gout and CKD. This Consensus Statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) discusses the evidence and/or lack thereof for the management of gout in people with CKD and identifies key areas for research to address the challenges faced in the management of gout and CKD. These discussions, which address areas for research both in general as well as related to specific medications used to treat gout flares or as ULT, are supported by separately published G-CAN systematic literature reviews. This Consensus Statement is not intended as a guideline for the management of gout in CKD; rather, it analyses the available literature on the safety and efficacy of drugs used in gout management to identify important gaps in knowledge and associated areas for research.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: